|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection.<i>See related commentary by Subbiah and Pal, p. 1646</i>.<i>This article is highlighted in the In This Issue feature, p. 1631</i>.
|
31575541 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR4 is therefore a promising target for the treatment of HCC harboring aberrant FGF19-FGFR4 signaling, and several FGFR4 inhibitors have advanced to clinical trial.
|
30403487 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF401 has remarkable antitumor activity in mice bearing HCC tumor xenografts and patient-derived xenograft models that are positive for FGF19, FGFR4, and KLB.
|
31409633 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the <i>FGF19-FGFR4</i> signaling pathway is a promising target for the treatment of HCC.
|
31167419 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many molecular alterations of the receptor and its ligands, specially FGF19, have been reported in several types of cancer, with special relevance in hepatocellular carcinoma.
|
31146605 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of importance, FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers.
|
31718608 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression.
|
31575540 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSION: We defined a FGF19-SOX18-FGFR4 positive feedback loop that played a pivotal role in HCC metastasis, and targeting this pathway may be a promising therapeutic option for the clinical management of HCC.
|
31529503 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study explored the potential of FGF19- and FGFR4-related biomarkers in predicting early tumour recurrence (ETR) and survival in patients with resectable hepatocellular carcinoma (HCC).
|
30698907 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we investigated the biological function of SNHG16 in HCC and showed that SNHG16 promoted liver cancer cells proliferation via the SNHG16/miR-302a-3p/FGF19 axis.
|
30784284 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data bona fide suggest the therapeutic potential of targeting the FXR-FGF19 axis to reduce hepatic BA synthesis in the control of BA-associated risk of fibrosis and hepatocarcinoma development.
|
30464200 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further investigation of FGF19/FGFR4 signaling is important for potential early diagnosis and therapeutic targeting in HCC patients.
|
29973237 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we hypothesize that the FGF19-FGFR4 axis may affect the effectiveness of sorafenib in the treatment of HCC.
|
28983785 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have demonstrated that FGF15 and FGF19 induce the activation of its receptor, FGF receptor 4 (FGFR4), which can promote hepatocellular carcinoma progression and regulate liver lipid metabolism.
|
29468415 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we present a novel and intriguing view on the putative possibility to target the FXR-FGF19 duo in order to offer a bona fide promising therapeutic approach to bile acid promoted hepatocarcinoma.
|
30223181 |
2018 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, our results offer preclinical proof of concept for H3B-6527 as a candidate therapeutic agent for HCC cases that exhibit increased expression of FGF19.<i></i>.
|
29247039 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interference with FGF19-FGFR4 signaling represents a novel strategy in HCC therapy.
|
28249259 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels.
|
28189755 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings show how FGF19 provides a cytoprotective role against ER stress by activating a FGFR4-GSK3β-Nrf2 signaling cascade, with implications for targeting this signaling node as a candidate therapeutic regimen for HCC management.<i></i>.
|
28951455 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis in HCC.
|
28069043 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma.
|
28178326 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data reveal a key role for the IL-6/STAT3 axis in potentiating FGF19-driven HCC in mice, a finding which may have translational relevance in HCC pathogenesis.
|
28508871 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ASP5878 potently suppressed the growth of the fibroblast growth factor 19-expressing hepatocellular carcinoma cell lines Hep3B2.1-7, HuH-7, and JHH-7.
|
27837028 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
|
27384874 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As FGF19 and its specific receptor FGFR4 are frequently amplified in HCC cells, selective targeting this signaling node may lend insights into a potential effective therapeutic approach for blocking metastasis of HCC.
|
26498355 |
2016 |